WebDoctor Encyclopedia

Childhood Soft-tissue sarcomas

Alveolar soft part sarcoma (ASPS)

Alveolar soft part sarcoma (ASPS) is a very rare, slow-growing soft-tissue cancer of teenagers and young adults, caused by the ASPSCR1-TFE3 gene fusion. It often spreads to the lungs and brain.

Medically reviewed Last reviewed October 17, 2026

What is alveolar soft part sarcoma?

Alveolar soft part sarcoma (ASPS) is a very rare cancer of the soft tissues. It usually grows deep in the muscles of the thigh or buttock in young adults, or in the head and neck, such as the tongue or eye socket, in children.

It gets its name from its appearance under the microscope. The tumour cells sit in small nests that look like the air sacs (alveoli) of the lung. It has nothing to do with the lung itself.

ASPS is caused by a gene fusion called ASPSCR1-TFE3. It tends to grow slowly and often causes no pain, so it can be present for a long time before it is found.

Despite slow growth, ASPS spreads early through the bloodstream, especially to the lungs and brain. Many people already have spread (metastases) when they are diagnosed.

Standard chemotherapy works poorly. However, immunotherapy with atezolizumab and drugs that block blood vessel growth have changed treatment in recent years. Many people live for years, even with metastatic disease.

1. Key facts at a glance

Feature Details
How common Fewer than 1% of soft-tissue sarcomas
Typical age Mostly 15-35; also children
Sex Slightly more common in females, especially under 25
Main sites Thigh and buttock (adults); head and neck, especially tongue and eye socket (children)
Cause Acquired ASPSCR1-TFE3 gene fusion
Spread Lungs, brain and bone; often present at diagnosis
Main treatments Surgery, radiotherapy, immunotherapy (atezolizumab) and anti-angiogenic drugs
Outlook Good for small, completely removed tumours; slow but persistent course when it has spread

2. Causes

ASPS is caused by a change in the tumour cells in which part of the X chromosome joins part of chromosome 17. This is written as der(17)t(X;17)(p11;q25). It fuses the ASPSCR1 gene with the TFE3 gene.

The fused protein acts as a switch that turns on many genes, including those that make new blood vessels (angiogenesis) and help cells use energy. This explains why ASPS tumours have such a rich blood supply and why drugs that block blood vessel growth can work.

Question Answer
Is it inherited? No. The fusion is acquired only in the tumour
Are there known lifestyle causes? No. Diet, smoking or injuries have not been shown to cause ASPS
Is it linked to other conditions? No known syndrome increases the risk

The same fusion is found in a rare kidney cancer (TFE3-rearranged renal cell carcinoma), but that tumour behaves differently.

2.1 Where ASPS grows

Site Who is affected Notes
Thigh and buttock Mainly adults and older teenagers The most common site; tumours are often deep inside large muscles and can reach 5-10 cm before they are noticed
Other limb and trunk muscles Adults Arm, shoulder, chest wall and back
Tongue Mainly children Usually found earlier because it is easy to see or feel; often small
Eye socket (orbit) Mainly children Causes a bulging eye; often small at diagnosis
Unusual sites Any age Female genital tract, bone, lung, stomach and other organs, rarely

3. How does it look?

3.1 On the body

Feature What it looks or feels like
Lump A soft or firm, deep, painless swelling that grows slowly over months or years
Pulsation Because of its rich blood supply, the lump may feel warm or pulsate, and a doctor may hear a whooshing sound (bruit)
Visible veins Swollen veins over the lump
Tongue A smooth swelling within the tongue in children
Eye socket A bulging eye or swelling of the eyelid

3.2 On scans

Test Typical findings
MRI A deep mass that is bright on both T1 and T2 images, with large winding blood vessels (flow voids) in and around it, and strong enhancement after contrast
Ultrasound A solid mass with very high blood flow on Doppler
CT chest Often shows multiple small round lung nodules, sometimes when the main tumour is still small
Brain MRI Recommended at diagnosis because of the risk of brain spread

3.3 Under the microscope

Feature Description
Pattern Nests of large cells separated by thin blood channels, giving an alveolar (air-sac) look; the centre of nests often falls apart
Cells Large, round or polygonal cells with plenty of pink, granular cytoplasm and prominent nucleoli
Crystals Rod-shaped crystals that stain with PAS and resist diastase digestion; very typical of ASPS
TFE3 stain Strong nuclear staining for TFE3
Genetic test FISH or sequencing shows the ASPSCR1-TFE3 fusion

4. Symptoms

Many people have few or no symptoms for a long time.

Symptom Details
Painless lump The most common first sign, usually in the thigh or buttock
Swelling that slowly grows Over months or years
Pain or numbness If the tumour presses on nerves
Tongue swelling Difficulty speaking or eating in children with tongue tumours
Eye symptoms Bulging eye, double vision or reduced vision with orbit tumours

4.1 Symptoms of spread

Site of spread Symptoms
Lungs Often none; sometimes cough, breathlessness or coughing blood
Brain Headaches, fits, weakness, speech or vision problems, or behaviour change
Bone Bone pain or a fracture

Sometimes lung or brain metastases are found before the main tumour.

5. Diagnosis

Step Purpose
MRI of the lump Shows size, depth, blood supply and nearby structures
Core needle biopsy At a sarcoma centre; the tumour bleeds easily, so experienced teams plan this
Pathology with TFE3 and genetic tests Confirms ASPS and excludes other tumours such as paraganglioma, renal cell carcinoma metastasis or granular cell tumour
CT of the chest Looks for lung metastases
MRI of the brain Looks for brain metastases
PET-CT or bone scan In some cases, for bone spread

6. Treatment

Treatment should be planned at a specialist sarcoma centre. The 2021 ESMO-EURACAN-GENTURIS guidelines cover soft-tissue sarcomas, including ASPS.

6.1 Localised disease

Treatment Details
Surgery Complete removal with a margin of healthy tissue is the main treatment and can cure localised ASPS
Radiotherapy Before or after surgery when margins are close or the tumour is large or deep
Chemotherapy Not routinely used, as standard sarcoma chemotherapy works poorly in ASPS

6.2 Metastatic or inoperable disease

Treatment Evidence and key points
Atezolizumab A PD-L1 immunotherapy. In a US trial, about 37% of people had their tumours shrink, often for a long time. Approved in the United States since 2022 for ASPS in adults and children aged 2 and over
Axitinib plus pembrolizumab In a phase 2 trial, more than half of people with ASPS responded
Cediranib Blocks blood vessel growth. In the CASPS trial it slowed tumour growth compared with placebo
Sunitinib and pazopanib Other anti-angiogenic tablets with activity in ASPS
Surgery for metastases Removing a few lung or brain metastases can help selected people
Stereotactic radiotherapy For brain or other metastases
Clinical trials Recommended where available

6.3 Side effects of treatment

Treatment Common side effects
Surgery Pain, wound problems, reduced muscle strength or movement depending on the site
Radiotherapy Skin redness, tiredness; later, stiffness or swelling
Anti-angiogenic tablets High blood pressure, diarrhoea, tiredness, sore hands and feet, thyroid problems, delayed wound healing
Immunotherapy Immune inflammation of the thyroid, skin, bowel, liver or lungs

6.4 How treatment decisions are made

Because ASPS is rare and often grows slowly, the team weighs several factors before choosing treatment:

Factor Why it matters
Size and site of the main tumour Determines whether surgery can remove it fully without major loss of function
Number and growth of metastases A few slow-growing lung spots may be watched for a while or removed; many or fast-growing ones usually need drug treatment
Brain metastases Often treated with surgery or stereotactic radiotherapy before or alongside drugs
Age Atezolizumab is approved for children aged 2 and over as well as adults in the United States; trial options differ for children
Symptoms and personal wishes Some people with stable disease prefer a period of active monitoring
Drug access Approvals and funding differ between countries, so clinical trials are often discussed

A short period of active surveillance with regular scans is sometimes reasonable for small, slow-growing lung metastases that cause no symptoms. Treatment starts when the disease grows or causes problems.

7. Outlook (prognosis)

ASPS is often described as slow but relentless. People may live for many years even when it has spread, but late spread and relapse are common.

Situation Approximate outlook
Small tumour (under 5 cm), completely removed, no spread Good; many are cured
Larger tumours Higher risk of later spread
Metastatic disease Long-term survival possible; older series reported about 60% alive at 5 years and about 15% at 20 years overall
Brain metastases Worse outlook, though local treatments can control them
Modern immunotherapy and anti-angiogenic drugs Have improved disease control

Children and young people with small tumours, especially in the head and neck, often do better.

8. Follow-up

What How often
Clinic visit and examination Every 3-6 months for at least 5 years
MRI of the original site Regularly in the first years
CT chest Every 3-6 months at first
Brain MRI Often included, especially if lung metastases are present
Long-term follow-up Continued for 10 years or more, because ASPS can spread late

9. Living with ASPS

Topic Practical advice
Young people Teenage and young adult cancer services offer support with school, work and relationships
Fertility Usually not affected by surgery alone; discuss before radiotherapy to the pelvis
Exercise and rehabilitation Physiotherapy after limb surgery helps restore strength
Blood pressure checks Important on anti-angiogenic tablets
Support Sarcoma charities and patient groups provide information and peer contact

10. Children and young people

ASPS is one of the sarcomas seen in older children and adolescents. In children, it more often arises in the tongue or eye socket, where it is noticed early and is usually small. This partly explains why children often have a better outlook than adults.

Children are treated in paediatric or teenage and young adult cancer centres, often within international sarcoma study groups. Surgery is again the main treatment. Radiotherapy is used carefully because of its long-term effects on growing tissue, and immunotherapy or targeted drugs are given for metastatic disease, often within trials.

11. Frequently asked questions

Question Answer
Is ASPS a lung cancer? No. “Alveolar” refers to its microscopic pattern. It is a sarcoma of soft tissue
Why does it spread to the brain? ASPS has a very rich blood supply and spreads through the blood. This is why brain scans are part of staging
Will chemotherapy help? Standard chemotherapy rarely helps. Immunotherapy and targeted tablets work better
Can I live a normal life with lung metastases? Many people do for years, because lung spots often grow slowly. Your team will monitor them closely
Is it inherited? No. It is caused by a gene fusion that develops only in the tumour

Resources

  1. WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
  2. Ladanyi, M. et al. (2001) ‘The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25’, Oncogene, 20(1), pp. 48-57.
  3. Folpe, A.L. and Deyrup, A.T. (2006) ‘Alveolar soft-part sarcoma: a review and update’, Journal of Clinical Pathology, 59(11), pp. 1127-1132.
  4. Lieberman, P.H. et al. (1989) ‘Alveolar soft-part sarcoma. A clinico-pathologic study of half a century’, Cancer, 63(1), pp. 1-13.
  5. Portera, C.A. Jr. et al. (2001) ‘Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution’, Cancer, 91(3), pp. 585-591.
  6. Paoluzzi, L. and Maki, R.G. (2019) ‘Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: a review’, JAMA Oncology, 5(2), pp. 254-260.
  7. Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
  8. Chen, A.P. et al. (2023) ‘Atezolizumab for advanced alveolar soft part sarcoma’, New England Journal of Medicine, 389(10), pp. 911-921.
  9. Wilky, B.A. et al. (2019) ‘Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial’, The Lancet Oncology, 20(6), pp. 837-848.
  10. Kummar, S. et al. (2013) ‘Cediranib for metastatic alveolar soft part sarcoma’, Journal of Clinical Oncology, 31(18), pp. 2296-2302.
  11. Judson, I. et al. (2019) ‘Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial’, The Lancet Oncology, 20(7), pp. 1023-1034.
  12. Nguyen, J. et al. (2023) ‘Randomized phase II trial of sunitinib or cediranib in alveolar soft part sarcoma’, Clinical Cancer Research, 29(7), pp. 1200-1208.
  13. National Cancer Institute (2026) Alveolar Soft Part Sarcoma. Available at: https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-soft-tissue-tumors/alveolar-soft-part-sarcomas (Accessed: October 2026).

Prepared by the editorial team, October 2026.